David Williams to Join INOVIQ Board
David Williams to Join INOVIQ Board
INOVIQ Limited (ASX: IIQ) has announced the appointment of David Williams as a Non-Executive Director and Chairman Elect, effective from the Annual General Meeting (AGM) scheduled for 29 November 2023. Mr Williams will succeed Dr Geoffrey Cumming, who has served as Chairman since the acquisition of Sienna Cancer Diagnostics in July 2020. Dr Cumming will continue to play a vital role on the board as a Non-Executive Director.
董事有限公司(澳交所股票代碼：IIQ)已宣佈委任David為董事非執行董事及候任主席，由定於2023年11月29日舉行的股東周年大會起生效。威廉姆斯將接替傑弗裡·卡明博士，後者自2020年7月收購西耶納癌症診斷公司以來一直擔任董事長。作為董事的非執行董事，卡明博士將繼續在董事會發揮至關重要的作用。
David Williams is an experienced director and investment banker with a track record in business development, mergers and acquisitions, and capital raising. He has extensive experience advising ASX-listed companies in the food, medical device and pharmaceutical sectors. Currently, Mr Williams serves as Chairman of PolyNovo (ASX:PNV) and RMA Global (ASX:RMY), and is the Managing Director of corporate advisory firm Kidder Williams.
David·威廉姆斯是一位經驗豐富的董事和投資銀行家，在業務開發、並購和融資方面有過往記錄。他在食品、醫療器械和製藥行業為澳大利亞證券交易所上市公司提供諮詢服務方面擁有豐富的經驗。目前，威廉姆斯先生是PolyNovo(澳交所股票代碼：PNV)和RMA Global(澳交所股票代碼：RMY)的董事長，也是企業諮詢公司Kidder Williams的董事董事總經理。
Mr Williams said, "I am excited by the opportunity to assist INOVIQ to move from Research and Development to bringing its exosome and precision diagnostic solutions into the hands of clinicians for patients. I am passionate about technologies that have a positive impact on the lives of patients. Even better if the technology can be a platform and building block for other technologies. INOVIQ has multiple synergistic technologies and a strong internal team with robust external collaborations. A focus on getting the technology to market quickly while developing the platform for other indications will reward shareholders."
威廉姆斯表示：“我很高興有機會幫助INOVIQ從研發轉向將其外顯體和精確診斷解決方案帶到臨床醫生手中，為患者服務。我對對患者生活有積極影響的技術充滿熱情。如果該技術可以成為其他技術的平臺和基石，那就更好了。INOVIQ擁有多項協同技術和強大的內部團隊，並與強大的外部合作。專注於將技術迅速推向市場，同時開發用於其他適應症的平臺將會回報股東。”
Shares in INOVIQ closed 0.79 per cent higher at 64 cents.
INOVIQ股價收盤上漲0.79%，至0.64美元。
Image from The Market Herald.
圖片來自《市場先驅報》。
譯文內容由第三人軟體翻譯。